Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Leukemia - 1 Nov 2005

Corm S, Biggio V, Roche-Lestienne C, Laï J-L, Yakoub-Agha I, Philippe N, Nicolini F-E, Facon T, Preudhomme C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Core Binding Factor Alpha 2 Subunit
Share to Drug Resistance, Neoplasm
Share to Genes, abl

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 16151468
DOI: 10.1038/sj.leu.2403931

Genes

BCR
RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.PMID 16151468Read ↗

Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.Semantic proximity Read ↗

Mechanisms and implications of imatinib resistance mutations in BCR-ABLSemantic proximity Read ↗

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Semantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.Semantic proximity Read ↗

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.Semantic proximity Read ↗

Characteristics of BCR–ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patientsSemantic proximity Read ↗

Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.Semantic proximity Read ↗

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.Semantic proximity Read ↗

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.Semantic proximity Read ↗

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.Semantic proximity Read ↗

BCR-ABL1 mutation ≠ ponatinib resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.